List view / Grid view
The appointment of Francis Cuss announced...
7 April 2013 | By Bristol-Myers Squibb Company
The appointment of Francis Cuss announced...
Yervoy also shortlisted for Prix Galien Prize in Germany...
17 October 2012 | By Bristol-Myers Squibb Company
Yervoy also shortlisted for Prix Galien Prize in Germany...
First project will be to develop and implement protocol for…
28 February 2012 | By Bristol-Myers Squibb Company
First project will be to develop and implement protocol for Phase II study in IPF...
Bristol-Myers Squibb to acquire Inhibitex for $26.00 per share in…
7 January 2012 | By Bristol-Myers Squibb
Bristol-Myers Squibb to acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger...
Licensing agreement for Bristol-Myers Squibb to develop and commercialize a…
26 October 2011 | By Bristol-Myers Squibb Company
Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination...
Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule…
21 July 2011 | By Bristol-Myers Squibb
Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company...
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food…
16 June 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.
For the Treatment of Patients with Newly Diagnosed or Previously-Treated…
25 March 2011 | By Bristol-Myers Squibb Company
For the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer...
